World Health Organization (WHO) issues warning on falsified medicines used for diabetes treatment and weight loss
WHO has been observing increased demand for semaglutide medicines as well as reports on falsification. This alert addresses 3 falsified batches of product (Ozempic), which have been detected in several countries, including Great Britain and Northern Ireland.
Source:
World Health Organization
SPS commentary:
Patients using these medicines should avoid buying medicines from unfamiliar or unverified sources, such as those that may be found online.
WHO is currently working on a rapid advice guideline on possible use of GLP-1 RAs, including semaglutides, for treatment of obesity in adults and as part of a more comprehensive model of care. NICE recommends semaglutide as an option for weight management, alongside a reduced-calorie diet and increased physical activity in adults, providing certain criteria are met.